| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $9.3M | -40.7% | +6.4% |
| R&D Expense | $14.4M | -32.1% | -0.4% |
| SG&A Expense | $4.8M | -18.8% | -12.1% |
| Operating Income | -$19.2M | +29.2% | +3.6% |
| Net Income | -$18.7M | +29.9% | -0.5% |
| EPS (Basic) | -$1.13 | +35.1% | +8.9% |
| EPS (Diluted) | -$1.13 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $50.9M | +28.8% | -45.0% |
| Current Assets | $54.6M | +27.0% | -42.4% |
| Total Assets | $57.5M | +23.7% | -42.2% |
| Current Liabilities | $21.0M | +2.6% | +68.9% |
| Total Liabilities | $45.9M | +99.9% | +191.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$55.3M | — | — |
| Investing Cash Flow | $5K | — | — |
| Financing Cash Flow | $34.6M | — | — |
| +35.1% |
| +8.9% |
| $11.6M |
| -50.8% |
| -86.2% |